These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1350 related items for PubMed ID: 10507773

  • 1. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [Abstract] [Full Text] [Related]

  • 2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [Abstract] [Full Text] [Related]

  • 3. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [Abstract] [Full Text] [Related]

  • 4. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 Sep 15; 21(18):3440-6. PubMed ID: 12668650
    [Abstract] [Full Text] [Related]

  • 5. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
    Pedersen-Bjergaard J, Pedersen M, Myhre J, Geisler C.
    Leukemia; 1997 Oct 15; 11(10):1654-60. PubMed ID: 9324285
    [Abstract] [Full Text] [Related]

  • 6. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL.
    J Clin Oncol; 2007 Feb 10; 25(5):493-500. PubMed ID: 17290056
    [Abstract] [Full Text] [Related]

  • 7. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ.
    Biol Blood Marrow Transplant; 2006 Oct 10; 12(10):1065-72. PubMed ID: 17084370
    [Abstract] [Full Text] [Related]

  • 8. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F.
    Haematologica; 1999 Nov 10; 84(11):1007-11. PubMed ID: 10553161
    [Abstract] [Full Text] [Related]

  • 9. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R, Gil-Fernández JJ, Muñoz E, Acevedo A, Sobrino MP, Fernández-Rañada JM.
    Sangre (Barc); 1998 Jun 10; 43(3):179-84. PubMed ID: 9741222
    [Abstract] [Full Text] [Related]

  • 10. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Morales MD, González FA, Villegas A, del Potro E, Díaz Mediavilla J, Martínez R, Alvarez A, Colomé JA.
    Sangre (Barc); 1992 Dec 10; 37(6):429-33. PubMed ID: 1293793
    [Abstract] [Full Text] [Related]

  • 11. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
    Bone Marrow Transplant; 2000 Aug 10; 26(4):383-8. PubMed ID: 10982284
    [Abstract] [Full Text] [Related]

  • 12. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE, Phillips GL.
    Stem Cells; 1994 Sep 10; 12(5):477-93. PubMed ID: 7804123
    [Abstract] [Full Text] [Related]

  • 13. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
    Zinzani PL, Fiacchini M, Mazza P, Gherlinzoni F, Bocchia M, Tura S.
    Haematologica; 1991 Sep 10; 76(4):305-10. PubMed ID: 1724437
    [Abstract] [Full Text] [Related]

  • 14. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E.
    Bone Marrow Transplant; 2004 Oct 10; 34(7):581-7. PubMed ID: 15273714
    [Abstract] [Full Text] [Related]

  • 15. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
    Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM.
    J Clin Oncol; 2005 Nov 01; 23(31):7994-8002. PubMed ID: 16204014
    [Abstract] [Full Text] [Related]

  • 16. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
    Seropian S, Nadkarni R, Jillella AP, Salloum E, Burtness B, Hu GL, Zelterman D, Cooper DL.
    Bone Marrow Transplant; 1999 Mar 01; 23(6):599-605. PubMed ID: 10217191
    [Abstract] [Full Text] [Related]

  • 17. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K, Utsumi M, Shimoyama M.
    Gan To Kagaku Ryoho; 1998 Dec 01; 25(14):2202-9. PubMed ID: 9881076
    [Abstract] [Full Text] [Related]

  • 18. Analysis of the risk of solid tumor following Hodgkin's disease.
    Maurizi Enrici R, Anselmo AP, Osti MF, Santoro M, Tombolini V, Mandelli F, Biagini C.
    Haematologica; 1997 Dec 01; 82(1):57-63. PubMed ID: 9107084
    [Abstract] [Full Text] [Related]

  • 19. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
    Valagussa P, Bonadonna G.
    Haematologica; 1998 Sep 01; 83(9):769-70. PubMed ID: 9825571
    [No Abstract] [Full Text] [Related]

  • 20. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J.
    Biol Blood Marrow Transplant; 1997 Jun 01; 3(2):98-106. PubMed ID: 9267670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.